Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes

Saxena, AR; Frias, JP; Gorman, DN; Lopez, RN; Andrawis, N; Tsamandouras, N; Birnbaum, MJ

Saxena, AR (通讯作者)，Pfizer Worldwide Res Dev & Med, Internal Med Res Unit, 1 Portland St, Cambridge, MA 02139 USA.

DIABETES OBESITY & METABOLISM, 2023; 25 (10): 2805

Abstract

Aim: To evaluate the tolerability, safety and pharmacodynamics of different dose escalation schemes of the oral small-molecule glucagon-like peptide-1......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索